SCHEMBL19212367

SCHEMBL19212367

COC(=O)COc1ccc(F)c([N+](=O)[O-])c1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.57
KDM4E B2RXH2 1/20 0.57
PTGS2 P35354 2/20 0.53
SMN1; SMN2 Q16637 5/20 0.47
RAB9A P51151 4/20 0.47
MEN1 O00255 3/20 0.47
KMT2A Q03164 3/20 0.47
NPC1 O15118 2/20 0.47
ALDH1A1 P00352 5/20 0.46
POLB P06746 1/20 0.46
MAPK1 P28482 1/20 0.46
RAPGEF3 O95398 1/20 0.45
TDP1 Q9NUW8 1/20 0.45
CYP1A2 P05177 1/20 0.44
GAA P10253 1/20 0.44
CYP2C19 P33261 1/20 0.44
HIF1A Q16665 1/20 0.44
LMNA P02545 3/20 0.44
RECQL P46063 1/20 0.43
HTT P42858 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31472484 0.89 PTGS2 (0.53) MAPTKDM4EPTGS2SMN1; SMN2RAB9A
SCHEMBL6986185 0.89 PTGS2 (0.53) MAPTKDM4EPTGS2SMN1; SMN2RAB9A
SCHEMBL18721152 0.87 PTGS2 (0.57) MAPTPTGS2SMN1; SMN2RAB9AMEN1
SCHEMBL17066157 0.86 MAPT (0.57) MAPTKDM4ESMN1; SMN2RAB9AMEN1
SCHEMBL31415261 0.86 MAPT (0.57) MAPTKDM4ESMN1; SMN2RAB9AMEN1
SCHEMBL17935270 0.85 MAPT (0.51) MAPTKDM4ESMN1; SMN2RAB9AMEN1
SCHEMBL23120941 0.84 PTGS2 (0.54) MAPTKDM4EPTGS2SMN1; SMN2RAB9A
SCHEMBL31415219 0.84 MAPT (0.51) MAPTKDM4ESMN1; SMN2RAB9AMEN1
SCHEMBL17009709 0.84 MAPT (0.51) MAPTKDM4ESMN1; SMN2RAB9AMEN1
SCHEMBL533967 0.83 MAPT (0.54) MAPTKDM4EPTGS2SMN1; SMN2RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240382600-A1 BIFUNCTIONAL DEGRADERS COMPRISING A TEAD BINDER NOVARTIS AG (CH) 2024-11-21 US disclosed
EP-4395828-A1 BIFUNCTIONAL DEGRADERS COMPRISING A TEAD BINDER Novartis AG (CH) 2024-07-10 EP disclosed
US-11969425-B2 Inhibitor of indoleamine-2,3-dioxygenase (IDO) INVENTISBIO LLC (US) 2024-04-30 US disclosed
CN-113896685-B Indoleamine-2, 3-dioxygenase (IDO) inhibitors 益方生物科技(上海)股份有限公司 2024-02-06 CN disclosed
US-20230391760-A1 HETEROCYCLIC GLP-1 AGONISTS GASHERBRUM BIO, INC. 2023-12-07 US disclosed
US-20230338373-A1 INHIBITOR OF INDOLEAMINE-2,3-DIOXYGENASE (IDO) INVENTISBIO LLC 2023-10-26 US disclosed
WO-2023031801-A1 BIFUNCTIONAL DEGRADERS COMPRISING A TEAD BINDER NOVARTIS AG (CH) 2023-03-09 WO disclosed
EP-3414224-B1 INHIBITOR OF INDOLEAMINE-2,3-DIOXYGENASE (IDO) INVENTISBIO LLC (US) 2022-03-23 EP disclosed
US-20220054486-A1 INHIBITOR OF INDOLEAMINE-2,3-DIOXYGENASE (IDO) INVENTISBIO LLC (US) 2022-02-24 US disclosed
CN-113896685-A Indoleamine-2, 3-dioxygenase (IDO) inhibitors 益方生物科技(上海)股份有限公司 2022-01-07 CN disclosed
US-10980807-B2 Inhibitor of indoleamine-2,3-dioxygenase (IDO) INVENTISBIO LLC (US) 2021-04-20 US disclosed
US-20200046697-A1 INHIBITOR OF INDOLEAMINE-2,3-DIOXYGENASE (IDO) INVENTISBIO LLC 2020-02-13 US disclosed
EP-3414224-A1 INHIBITOR OF INDOLEAMINE-2,3-DIOXYGENASE (IDO) Inventisbio Inc. (KY) 2018-12-19 EP disclosed
WO-2017139414-A1 INHIBITOR OF INDOLEAMINE-2,3-DIOXYGENASE (IDO) INVENTISBIO INC. (KY) 2017-08-17 WO disclosed
WO-2017139414-A1 INHIBITOR OF INDOLEAMINE-2,3-DIOXYGENASE (IDO) INVENTISBIO INC. (KY) 2017-08-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240382600-A1 BIFUNCTIONAL DEGRADERS COMPRISING A TEAD BINDER YAP1, JMJD7, TOR1AIP1 MAPT 212/4885KDM4E 1085/4885PTGS2 4349/4885
US-20230338373-A1 INHIBITOR OF INDOLEAMINE-2,3-DIOXYGENASE (IDO) IDO1, IDO2, INMT MAPT 1957/4885KDM4E 430/4885PTGS2 374/4885
US-20230391760-A1 HETEROCYCLIC GLP-1 AGONISTS GLP1R, GIPR, GCGR MAPT 3873/4885KDM4E 3398/4885PTGS2 2712/4885
US-11969425-B2 Inhibitor of indoleamine-2,3-dioxygenase (IDO) IDO1, IDO2, INMT MAPT 1957/4885KDM4E 430/4885PTGS2 374/4885
US-20220054486-A1 INHIBITOR OF INDOLEAMINE-2,3-DIOXYGENASE (IDO) IDO1, IDO2, INMT MAPT 1957/4885KDM4E 430/4885PTGS2 374/4885
US-20200046697-A1 INHIBITOR OF INDOLEAMINE-2,3-DIOXYGENASE (IDO) IDO1, IDO2, INMT MAPT 1957/4885KDM4E 430/4885PTGS2 374/4885
US-10980807-B2 Inhibitor of indoleamine-2,3-dioxygenase (IDO) IDO1, IDO2, INMT MAPT 1957/4885KDM4E 430/4885PTGS2 374/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.